View Archive »
About The Cover
Paclitaxel inhibition of cell migration. A mixed culture of wild-type CHO cells and HAβ3-5 cells was scratched to make a wound and the cells were allowed to migrate for 24 h in the absence or presence of 10 nM paclitaxel. The cells were then stained for α-tubulin (red), HAβ3-tubulin (green), and DNA (blue). See Ganguly et al.
|
|
Table of Contents
|
| Mycoplasmas and Human prostate cancer: An exciting but cautionary note |
|
https://doi.org/10.18632/oncotarget.282
Shyh-Ching Lo, and Shien Tsai
|
| 352-355 |
|
| Proteotoxic stress targeted therapy PSTT |
|
https://doi.org/10.18632/oncotarget.284
Michael Y. Sherman
|
| 356-357 |
Brief Reports
|
| Xenotropic murine leukemia virusrelated virus XMRV in prostate cancer cells likely represents a laboratory artifact |
|
https://doi.org/10.18632/oncotarget.287
Jiawen Yang, Partho Battacharya, Ruchi Singhal, and Eugene S. Kandel
|
| 358-362 |
Research Papers
|
| Netrin1 overexpression is predictive of ovarian malignancies |
|
https://doi.org/10.18632/oncotarget.258
Anastasios D. Papanastasiou, Georgios Pampalakis, Dionyssios Katsaros, and Georgia Sotiropoulou
|
| 363-367 |
|
| Class III βTubulin Counteracts the Ability of Paclitaxel to Inhibit Cell Migration |
|
https://doi.org/10.18632/oncotarget.250
Anutosh Ganguly, Hailing Yang, and Fernando Cabral
|
| 368-377 |
|
| Network Modeling of MDM2 InhibitorOxaliplatin Combination Reveals Biological Synergy in wtp53 solid tumors |
|
https://doi.org/10.18632/oncotarget.269
Asfar S. Azmi, Sanjeev Banerjee, Shadan Ali, Zhiwei Wang, Bin Bao, Frances WJ Beck, Anthony F. Shields, Philip Philip, Fazlul H. Sarkar, and Ramzi M. Mohammad
|
| 378-392 |
|
| No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis |
|
https://doi.org/10.18632/oncotarget.278
Katharina Bluemlein, Nana-Maria Grüning, René G. Feichtinger, Hans Lehrach, Barbara Kofler, and Markus Ralser
|
| 393-400 |
Research Perspectives
|
| YB1 drives preneoplastic progression: Insight into opportunities for cancer prevention |
|
https://doi.org/10.18632/oncotarget.276
Alastair H. Davies, and Sandra E. Dunn
|
| 401-406 |
|
| Casein kinase 2 phosphorylation of Hsp90 threonine 22 modulates chaperone function and drug sensitivity |
|
https://doi.org/10.18632/oncotarget.272
Mehdi Mollapour, Shinji Tsutsumi, Yeong Sang Kim, Jane Trepel, and Len Neckers
|
| 407-417 |
|
| Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link |
|
https://doi.org/10.18632/oncotarget.277
Simone Fulda
|
| 418-421 |
|
| cJUN prevents methylation of p16INK4a and Cdk6: the villain turned bodyguard |
|
https://doi.org/10.18632/oncotarget.279
Karoline Kollmann, Gerwin Heller, and Veronika Sexl
|
| 422-427 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC
